commun
respiratori
viru
infect
primarili
consid
infect
children
gener
howev
past
two
decad
becom
clear
virus
caus
seriou
infect
requir
medic
attent
particularli
infant
elderli
immunocompromis
patient
histor
common
caus
respiratori
infect
cancer
patient
thought
opportunist
bacteria
fungi
newer
diagnost
method
reveal
respiratori
virus
caus
seriou
morbid
mortal
patient
includ
leukemia
patient
hematopoiet
stem
cell
transplant
hsct
recipi
mani
virus
known
caus
respiratori
tract
infect
common
hospit
cancer
patient
influenza
virus
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
howev
respiratori
virus
caus
respiratori
infect
cancer
patient
includ
rhinovirus
enterovirus
coronavirus
human
metapneumovirus
hmpv
adenovirus
well
cytomegalovirus
herp
simplex
varicella
zoster
virus
chapter
discuss
common
clinic
present
diagnost
method
treatment
prevent
measur
respiratori
viru
infect
gener
cancer
patient
particular
tabl
data
septemb
februari
period
institut
fig
demonstr
cyclic
pattern
three
major
respiratori
virus
rsv
influenza
piv
season
influenza
infect
cancer
patient
report
start
juli
peak
octob
due
pandem
influenza
viru
recent
total
case
influenza
parainfluenza
rsv
identifi
institut
septemb
februari
fig
case
hsct
recipi
rsv
infect
present
wide
array
upper
lower
respiratori
symptom
incub
period
day
adult
infant
young
children
primari
infect
start
upper
respiratori
tract
rhinorrhea
lowgrad
fever
cough
may
progress
lower
respiratori
infect
lri
bronchiol
pneumonia
stage
patient
seek
medic
attent
also
like
involv
sinus
middl
ear
rsv
known
caus
apnea
infant
although
mechan
action
remain
unknown
older
children
adult
present
upper
respiratori
tract
symptom
may
also
constitut
symptom
fever
malais
rsv
upper
respiratori
infect
uri
also
progress
lower
respiratori
tract
particularli
institution
adult
sever
combin
immunodefici
leukemia
hsct
lung
transplant
recipi
patient
may
present
wheez
short
breath
without
underli
comorbid
known
hyperact
airway
almost
elderli
patient
rsv
infect
report
wheez
rsv
infect
begin
uri
progress
lri
hsct
recipi
lead
respiratori
failur
morbid
mortal
earli
studi
describ
mortal
rate
hsct
recipi
risk
factor
progress
lri
includ
lymphopenia
older
age
stage
malign
graftversushost
diseas
ribavirin
treatment
torr
et
al
found
high
apach
ii
score
give
aerosol
ribavirin
treatment
independ
predictor
progress
pneumonia
leukemia
patient
uri
treat
aerosol
ribavirin
less
like
untreat
patient
develop
pneumonia
vs
p
die
rsv
infect
vs
p
overal
mortal
rate
studi
solid
organ
transplant
patient
rsv
infect
may
present
dyspnea
cough
fever
wheez
progress
pneumonia
patient
lung
transplant
recipi
higher
frequenc
rsv
pneumonia
report
mortal
rate
low
mortal
rate
also
low
kidney
transplant
recipi
pediatr
liver
transplant
patient
pohl
et
al
report
mortal
rate
rsv
pneumonia
earli
infect
onset
preexist
lung
diseas
predictor
sever
diseas
children
genet
polymorph
cytokin
chemokinerel
gene
interleukin
il
gene
relat
potenti
viruscel
surfac
interact
cell
signal
spa
spd
associ
sever
rsv
infect
data
hiv
patient
rsv
infect
scarc
howev
cohort
studi
miller
et
al
perform
winter
found
evid
influenza
rsv
parainfluenza
adenoviru
enteroviru
infect
bronchoscop
alveolar
lavag
fluid
patient
rsv
diagnos
basi
clinic
infant
lri
outbreak
period
rsv
infect
adult
clinic
differenti
viral
infect
caus
upper
respiratori
symptom
specif
diagnosi
rsv
must
detect
respiratori
secret
nasal
aspir
wash
like
give
posit
rsv
test
young
children
nasal
aspir
wash
obtain
nasopharyng
swab
throat
swab
may
use
immunocompromis
patient
like
develop
lri
due
rsv
aspir
bronchoalveolar
lavag
perform
gold
standard
diagnos
rsv
remain
identif
viru
caus
typic
syncytia
cultur
cell
viral
cultur
may
take
day
shell
vial
cultur
week
routin
cultur
becom
posit
make
isol
less
relev
set
avail
method
includ
antigen
detect
enzymelink
immunosorb
assay
elisa
immunoflouresc
assay
polymeras
chain
pcr
test
fan
et
al
report
sensit
rsv
detect
use
rapid
antigen
test
elisa
pcr
test
shown
sensit
direct
antigen
detect
immunocompromis
patient
rsv
treatment
focus
reduc
symptom
sever
prevent
lri
nonsteroid
antiinflammatori
drug
antihistamin
use
patient
uri
ribavirin
nucleosid
analog
vitro
activ
rsv
approv
unit
state
food
drug
administr
treatment
rsv
infect
children
two
schedul
aerosol
ribavirin
use
immunocompromis
patient
continu
intermitt
continu
schedul
daili
dose
g
concentr
mgml
deliv
h
via
small
particl
aerosol
gener
unit
administ
via
face
mask
tent
intermitt
schedul
concentr
mgml
deliv
h
everi
h
aerosol
ribavirin
may
benefici
certain
adult
children
lri
earli
use
shown
retrospect
studi
reduc
morbid
mortal
hsct
recipi
patient
hematolog
malign
particularli
infect
treat
earli
howev
effect
solid
organ
transplant
patient
remain
unknown
rsvspecif
monoclon
antibodi
palivizumab
demonstr
therapeut
benefit
major
studi
conduct
children
although
combin
ribavirin
intraven
immunoglobulin
ivig
palivizumab
evalu
random
trial
sometim
use
sever
ill
patient
rsv
pneumonia
especi
hsct
recipi
given
high
mortal
rate
infect
patient
risk
progress
lri
aerosol
ribavirin
consid
earli
stage
recent
trial
demonstr
intermitt
continu
schedul
aerosol
ribavirin
prevent
progress
lri
patient
rsv
uri
hematolog
malign
includ
hsct
recipi
respect
rsv
infect
may
acquir
nosocomi
thu
specif
infect
control
measur
implement
deal
patient
known
suspect
infect
briefli
patient
isol
privat
room
possibl
appropri
personnel
protect
equip
use
ie
dispos
glove
mask
gown
licens
vaccin
avail
rsv
howev
two
agent
rsvivig
palivizumab
use
prevent
rsv
infect
rsvivig
studi
children
younger
month
sever
lung
diseas
born
prematur
remov
market
random
doubleblind
placebocontrol
studi
children
found
palivizumab
recipi
rel
reduct
rsv
hospit
p
twentyon
children
die
palivizumab
group
vs
placebo
group
death
attribut
palivizumab
palivizumab
easier
administ
regular
ivig
must
given
h
interfer
vaccin
howev
rsvivig
ivig
may
provid
addit
protect
respiratori
virus
well
influenza
typic
short
incub
period
abrupt
onset
symptom
headach
fever
chill
myalgia
malais
along
respiratori
symptom
runni
nose
cough
sore
throat
also
present
febril
uri
constitut
manifest
fewtono
respiratori
symptom
influenza
progress
pneumonia
otherwis
healthi
person
particularli
patient
comorbid
lung
diseas
heart
diseas
diabet
renal
diseas
hemoglobinopathi
immunocompromis
individu
resid
nurs
home
chronic
care
facil
individu
year
age
primari
pneumonia
occur
influenza
viru
directli
involv
lung
suspect
clinic
symptom
progress
high
fever
dyspnea
hypoxemia
influenza
viru
infect
also
affect
epithelium
tracheobronchi
tree
lead
impair
defens
secondari
bacteri
pneumonia
studi
leukemia
patient
influenza
infect
patient
develop
pneumonia
cough
dyspnea
common
manifest
half
patient
lymphopenia
incid
influenza
infect
hsct
recipi
report
mortal
rate
mainli
due
respiratori
failur
one
studi
patient
develop
influenza
hsct
present
pneumonia
present
uri
experienc
progress
lri
risk
factor
associ
progress
lri
lymphopenia
day
transplant
ie
pneumonia
develop
commonli
among
infect
earlier
transplant
wherea
use
system
steroid
autolog
stem
cell
transplant
appear
protect
xray
includ
diffus
interstiti
pattern
focal
infiltr
among
patient
solid
organ
transplant
lung
transplant
recipi
highest
risk
influenza
viru
infect
initi
present
patient
may
alway
respiratori
tract
ill
present
nonspecif
gastrointestin
symptom
howev
patient
requir
hospit
alway
present
pneumonia
progress
bronchiol
obliteran
characterist
chronic
lung
reject
infect
also
report
patient
postren
transplant
influenza
pneumonia
often
acut
high
fever
cough
dyspnea
cyanosi
leukopenia
thrombocytopenia
influenza
infect
diagnos
clinic
exhibit
classic
syndrom
epidem
howev
virus
produc
syndrom
influenza
infect
produc
respiratori
syndrom
confirmatori
test
detect
viru
viral
antigen
nasal
wash
throat
swab
respiratori
tract
secret
bronchoalveolar
lavag
specimen
need
sporad
case
immunocompromis
patient
viral
cultur
remain
gold
standard
diagnosi
take
h
yield
result
sputum
nasal
wash
nose
swab
superior
throat
swab
diagnosi
rapid
antigen
test
use
immunoflouresc
assay
enzym
immunoassay
pcrbase
test
use
frequent
clinic
set
result
test
obtain
hour
good
sensit
specif
obtain
earli
sever
ill
pcrbase
assay
sensit
rapid
antigen
test
diagnos
influenza
b
often
use
avail
cost
sampl
obtain
within
h
appear
symptom
accur
result
two
class
drug
avail
treat
influenza
infect
neuraminidas
inhibitor
zanamivir
oseltamivir
activ
influenza
b
virus
inhibitor
amantadin
rimantadin
activ
influenza
virus
amantadin
effect
influenza
b
resist
report
novel
viru
resist
oseltamivir
increas
season
viru
tabl
therapi
initi
earli
possibl
prefer
within
h
symptom
onset
zanamivir
oseltamivir
use
extens
treat
influenza
b
shown
reduc
mean
durat
symptom
day
use
within
h
symptom
onset
neuraminidas
inhibitor
shown
significantli
decreas
incid
complic
associ
influenza
develop
pneumonia
compar
placebo
common
side
effect
oseltamivir
nausea
vomit
although
toxic
report
central
nervou
system
side
effect
anxieti
insomnia
impair
think
confus
lightheaded
hallucin
report
amantadin
use
newer
ni
inhibitor
includ
parenter
prepar
develop
mainstay
influenza
prophylaxi
gener
popul
administr
influenza
vaccin
annual
vaccin
recommend
mani
year
peopl
high
risk
complic
includ
older
year
resid
nurs
home
facil
adult
children
chronic
pulmonari
cardiovascular
condit
adult
children
hospit
previou
year
women
second
third
trimest
immunocompromis
patient
healthcar
worker
famili
member
high
risk
prior
onset
influenza
season
american
committe
immun
practic
recent
recommend
vaccin
contraind
current
two
type
vaccin
avail
intramuscular
inactiv
viru
vaccin
intranas
attenu
viru
vaccin
intranas
form
use
healthi
individu
age
year
use
vaccin
immunocompromis
patient
individu
signific
allergi
egg
acut
febril
ill
given
vaccin
advisori
committe
immun
practic
recommend
immunocompromis
individu
vaccin
prior
influenza
season
receiv
daili
chemoprophylaxi
antivir
medic
outbreak
influenza
chemoprophylaxi
may
use
patient
high
risk
complic
vaccin
contraind
like
complet
protect
antivir
drug
administ
patient
within
first
month
hsct
document
graftversushost
diseas
unvaccin
healthcar
worker
care
immunocompromis
individu
resid
longterm
care
institut
outbreak
period
american
societi
blood
marrow
transplant
asbmt
guidelin
prevent
infect
hsct
recipi
recommend
annual
inactiv
influenza
vaccin
begin
season
stem
cell
transplant
vaccin
may
given
month
hsct
also
recommend
prophylaxi
preemptiv
treatment
commun
nosocomi
outbreak
influenza
hsct
recipi
regardless
vaccin
statu
within
month
transplant
month
posttranspl
gvhd
andor
immunosuppress
drug
use
chemoprophylaxi
depend
suscept
pattern
viru
piv
infect
wide
spectrum
present
simpl
uri
lifethreaten
complic
pneumonia
incub
period
usual
day
young
children
may
present
coryza
sore
throat
hoars
cough
chest
xray
reveal
interstiti
infiltr
adult
infect
mild
immunocompromis
individu
infect
progress
lower
respiratori
tract
ill
includ
pneumonia
caus
prolong
ill
even
death
piv
usual
present
uri
larg
studi
hsct
recipi
sever
year
piv
infect
document
case
communityacquir
patient
undergon
hsct
particular
risk
develop
sever
pivassoci
pneumonia
wendt
et
al
report
mortal
rate
coinfect
aspergillu
fumigatu
common
mechan
ventil
found
signific
risk
factor
piv
pneumoniaassoci
mortal
one
studi
factor
associ
progress
includ
neutropenia
within
month
prior
infect
apach
ii
score
higher
pulmonari
coinfect
studi
also
found
mortal
rate
around
differ
treat
treat
aerosol
ribavirin
patient
undergon
solid
organ
transplant
appear
increas
risk
develop
sever
piv
ill
studi
report
one
studi
lung
transplant
patient
found
piv
infect
patient
develop
major
treat
aerosol
ribavirin
one
recov
except
croup
young
children
clinic
pattern
piv
infect
similar
respiratori
virus
distinguish
basi
symptom
alon
commun
outbreak
presumpt
diagnosi
made
howev
confirm
laboratori
test
may
appropri
immunocompromis
individu
viru
detect
respiratori
tract
secret
nasal
wash
nasal
swab
throat
swab
bronchoalveolar
lavag
specimen
viral
cultur
remain
gold
standard
diagnosi
take
day
yield
result
rapid
antigen
detect
immunofluoresc
elisa
use
sensit
high
recent
pcrbase
assay
sensit
high
specif
manag
piv
infect
mostli
support
pivdirect
antivir
therapi
licens
us
food
drug
administr
ribavirin
shown
activ
viru
vitro
anim
model
use
occasion
treat
immunocompromis
patient
sever
piv
infect
one
case
seri
report
decreas
piv
viral
load
clinic
improv
aerosol
ribavirin
treatment
children
sever
immunodefici
nichol
et
al
report
aerosol
ribavirin
reduc
viral
shed
mortal
rate
hsct
recipi
infect
progress
lower
respiratori
tract
data
also
show
appar
benefit
aerosol
ribavirin
mortal
rate
hsct
recipi
leukemia
patient
hand
combin
methylprednisolon
intraven
oral
ribavirin
appar
use
success
treat
piv
pneumonia
hsct
heart
transplant
recipi
respect
current
licens
vaccin
avail
prevent
piv
infect
henc
infect
control
measur
play
import
role
contain
spread
infect
patient
suspect
confirm
infect
isol
personnel
protect
equip
use
adenoviru
infect
transmit
either
inhal
aerosol
viru
inocul
viru
conjunctiv
sac
fecalor
rout
subgroup
type
variou
type
subgroup
b
c
associ
pneumonia
hepat
serotyp
associ
outbreak
acut
diseas
militari
recruit
mostli
winter
spring
type
common
children
present
acut
upper
respiratori
tract
ill
progress
lower
respiratori
diseas
type
less
common
caus
sever
diseas
adult
infect
due
adenoviru
character
sore
throat
gradual
onset
fever
cough
coryza
region
lymphadenopathi
commonli
seen
common
clinic
symptom
besid
respiratori
symptom
fever
diarrhea
adenoviru
infect
common
hsct
occur
local
ill
part
dissemin
associ
delay
engraft
graft
failur
infect
due
adenoviru
hsct
recipi
report
incid
commonli
report
allogen
hsct
recipi
autolog
transplant
recipi
vs
mortal
rate
high
group
report
also
suggest
incid
adenoviru
infect
patient
hsct
may
rise
due
transplant
practic
dissemin
may
occur
without
respiratori
tract
symptom
diseas
develop
almost
organ
caus
gastrointestin
diseas
hepat
nephriti
pneumonia
conjunct
thrombot
thrombocytopen
purpura
pancreat
hemorrhag
cystiti
viremia
may
present
detect
case
dissemin
diseas
adenoviru
known
fatal
even
absenc
respiratori
tract
involv
howev
pneumonia
present
mortal
report
higher
vs
coinfect
aspergillu
spp
bacteria
nocardia
legionella
spp
mycobacterium
tubercul
frequent
seen
patient
popul
risk
factor
adenoviru
infect
includ
gvhd
unrel
donor
total
bodi
irradi
tcell
deplet
younger
age
year
old
chronic
diseas
recent
transplant
degre
tcell
deplet
posttranspl
suppress
tcell
function
import
one
adenoviru
type
associ
sever
infect
hsct
recipi
report
adenoviru
infect
solid
organ
transplant
patient
viru
involv
donor
organ
led
pneumonia
hepat
hemorrhag
cystiti
nephriti
enterocol
dissemin
diseas
patient
previou
liver
transplant
adenoviru
pneumonia
report
preval
mortal
rate
serotyp
known
associ
hepat
wherea
serotyp
commonli
associ
pneumonia
lung
transplant
recipi
one
studi
found
adenoviru
infect
earli
complic
follow
surgeri
preval
rate
progress
adenoviru
infect
known
associ
graft
loss
progress
bronchiol
obliteran
death
adenoviru
infect
suspect
case
acut
respiratori
diseas
militari
recruit
outbreak
case
infect
caus
viru
differenti
caus
respiratori
virus
clinic
present
alon
definit
diagnosi
establish
viral
cultur
detect
specif
viral
antigen
viral
cultur
remain
gold
standard
identif
adenoviru
nasopharyng
aspir
swab
throat
swab
sputum
sampl
bronchoalveolar
lavag
use
depend
site
infect
cytopath
effect
seen
human
cell
line
hela
cervix
lung
hek
human
embryon
kidney
larynx
strain
adenoviru
except
type
adenoviru
grow
well
hek
cell
adenovirusspecif
enzym
immunoassay
elisa
immunofluoresc
assay
use
detect
presenc
viru
clinic
sampl
rapid
test
suffer
sensit
pcrbase
assay
detect
adenoviru
dna
varieti
clinic
specimen
better
sensit
viral
load
quantif
use
tool
measur
prognosi
monitor
clinic
respons
viral
load
higher
copiesml
associ
increas
likelihood
death
random
clinic
trial
treatment
adenoviru
infect
immunocompromis
patient
patient
manag
use
symptombas
treatment
support
therapi
cidofovir
current
use
immunocompromis
patient
sinc
shown
decreas
plasma
viral
load
hsct
recipi
although
cidofovir
activ
strain
adenoviru
vitro
retrospect
data
avail
efficaci
cidofovir
hsct
solid
organ
transplant
recipi
nephrotox
commonli
encount
drug
use
caution
two
accept
regimen
mgkg
everi
week
mgkg
time
per
week
latter
associ
less
nephrotox
oral
activ
ether
lipidest
prodrug
cidofovir
hpmpa
develop
promis
result
vitro
experi
phase
trial
test
five
adenoviru
serotyp
shown
activ
unmodifi
parent
compound
intraven
ribavirin
use
report
case
result
conflict
final
anoth
treatment
option
use
adenovirusspecif
donor
tcell
infus
shown
feasibl
effect
protect
children
complic
due
adenoviru
infect
caus
signific
decreas
viral
load
current
vaccin
avail
adenoviru
infect
oral
partial
attenu
vaccin
contain
entericco
capsul
use
restrict
militari
routin
infect
control
practic
recommend
civilian
popul
special
must
taken
contact
droplet
exposur
hsct
recipi
high
risk
adenoviru
infect
weekli
pcr
surveil
viremia
preemptiv
treatment
cidofovir
use
individu
rhinoviru
infect
may
asymptomat
symptom
occur
typic
common
cold
commonli
rhinorrhea
sneez
associ
nasal
congest
infect
due
rhinoviru
incub
period
day
adult
characterist
experi
sneez
nasal
obstruct
discharg
along
cough
sore
scratchi
throat
sinus
commonli
involv
ill
rhinosinus
symptom
may
last
day
usual
resolv
complic
fever
usual
associ
adult
ill
children
hand
may
experi
fever
cough
nasal
discharg
obstruct
addit
durat
symptom
may
longer
although
bronchiti
bronchiol
bronchopneumonia
report
children
rhinoviru
usual
major
caus
lower
respiratori
ill
howev
import
caus
exacerb
asthma
chronic
obstruct
pulmonari
diseas
children
adult
lri
elderli
retrospect
studi
adult
rhinoviru
infect
undergon
hsct
found
patient
develop
eventu
die
pneumonia
one
patient
found
coinfect
aspergillu
spp
autopsi
patient
interstiti
pneumon
andor
acut
respiratori
distress
syndrom
studi
perform
anoth
institut
report
hsct
recipi
rhinoviru
infect
develop
pneumonia
die
studi
communityacquir
pneumonia
immunocompromis
patient
hsct
solid
organ
transplant
hiv
infect
receiv
steroid
chemotherapi
rhinoviru
respons
case
mortal
rate
find
suggest
rhinoviru
may
caus
sever
complic
immunocompromis
patient
previous
thought
mani
virus
caus
common
cold
symptom
definit
diagnosi
made
basi
present
symptom
rhinovirus
commonli
associ
cold
definit
diagnosi
made
isol
viru
nasal
wash
nasal
secret
specimen
tissu
cultur
newer
diagnost
method
realtim
reversetranscript
pcr
rtpcr
use
howev
test
frequent
perform
given
selflimit
natur
infect
specif
antivir
treatment
avail
rhinoviru
infect
case
manag
support
care
use
antihistamin
decongest
nonsteroid
antiinflammatori
drug
given
number
rhinoviru
serotyp
known
caus
infect
effect
vaccin
unlik
develop
near
futur
infect
control
measur
hand
isol
patient
known
suspect
rhinoviru
infect
help
contain
spread
viru
hmpv
usual
caus
mild
infect
short
durat
day
selflimit
incub
period
day
common
present
symptom
adult
cough
nasal
congest
rhinorrhea
dyspnea
hoars
wheez
children
often
present
cough
rhiniti
fever
wheez
recent
studi
patient
hematolog
malign
reveal
incid
hmpv
infect
nine
patient
undergon
hsct
pneumonia
three
patient
die
anoth
studi
hsct
recipi
detect
presenc
hmpv
bronchoalveolar
lavag
specimen
patient
present
fever
cough
nasal
congest
sore
throat
within
first
day
transplant
infect
progress
respiratori
failur
pulmonari
hemorrhag
cultureneg
septic
shock
mortal
rate
patient
hmpv
growth
cultur
slow
unreli
make
method
diagnosi
impract
present
symptom
similar
infect
caus
acut
respiratori
ill
make
clinic
diagnosi
imposs
pcrbase
method
use
diagnos
infect
center
specif
antivir
therapi
exist
hmpv
infect
vitro
studi
demonstr
ribavirin
activ
viru
howev
clinic
studi
report
immun
serum
globulin
may
neutral
viru
demonstr
one
vitro
studi
anecdot
lung
transplant
recipi
respiratori
failur
secondari
hmpv
pneumonia
treat
success
aerosol
ribavirin
use
gener
prevent
measur
patient
known
suspect
hmpv
infect
help
reduc
rate
transmiss
vaccin
current
avail
viru
clinic
manifest
coronaviru
infect
similar
rhinoviru
infect
common
symptom
rhinorrhea
throat
congest
fever
middl
ear
may
also
affect
lead
effus
acut
otiti
media
especi
children
incub
period
day
durat
ill
shorter
rhinoviru
infect
mean
day
subtyp
sarscov
slightli
longer
incub
period
day
immunocompromis
adult
coronavirus
caus
lower
respiratori
tract
infect
recent
case
seri
found
infect
rate
among
immunocompromis
patient
significantli
higher
compar
immunocompet
patient
vs
larg
studi
conduct
cancer
patient
immunocompromis
individu
case
report
folz
elkordi
report
patient
undergon
autolog
hsct
diagnos
coronaviru
lri
patient
develop
fever
sore
throat
cough
sever
hypoxia
treat
success
use
support
measur
kumar
et
al
describ
patient
develop
fatal
sever
acut
respiratori
syndrom
sar
liver
transplant
epidemiolog
infect
suspect
late
fall
winter
outbreak
howev
practic
method
avail
confirm
infect
except
pcrbase
test
use
diagnos
coronaviru
infect
institut
similar
rhinoviru
specif
antivir
therapi
avail
coronaviru
patient
respond
well
support
treatment
nonsteroid
antiinflammatori
drug
decongest
antihistamin
gener
prevent
measur
must
use
around
patient
coronaviru
infect
hand
wash
dispos
infect
materi
care
proper
disinfect
help
prevent
spread
viru
vaccin
viru
develop
clinic
pictur
enteroviru
infect
similar
rhinoviru
infect
specif
symptom
associ
viru
immunocompromis
patient
report
develop
central
nervou
system
infect
chronic
dissemin
infect
dermatomyositislik
syndrom
enteroviru
infect
studi
respiratori
tract
infect
hematolog
malign
patient
patient
enteroviru
infect
hsct
recipi
develop
pneumonia
studi
spain
report
four
hsct
recipi
develop
enteroviru
infect
mortal
rate
find
demonstr
immunocompromis
patient
may
risk
lower
respiratori
tract
infect
death
enteroviru
infect
enterovirus
isol
cell
cultur
nasopharyng
throat
swab
pcrbase
test
use
amplifi
viral
rna
throat
swab
cerebrospin
fluid
tissu
diagnosi
isol
viru
throat
clinic
signific
stool
viru
shorter
durat
shed
throat
enteroviru
infect
selflimit
requir
specif
treatment
intens
care
may
requir
central
nervou
system
cardiac
hepat
infect
ivig
use
patient
sever
infect
specif
antivir
therapi
avail
respiratori
virus
group
common
caus
acut
infecti
ill
develop
societi
varieti
virus
caus
infect
ill
age
group
presenc
high
frequenc
throughout
year
describ
risk
exposur
person
time
includ
immunocompromis
person
resid
commun
immunocompromis
state
mani
cancer
patient
constitut
basi
frequent
failur
host
promot
normal
rapid
recoveri
acut
respiratori
viral
infect
result
sever
prolong
infect
caus
signific
morbid
mortal
patient
respiratori
virus
preval
prone
produc
lower
respiratori
ill
pneumonia
healthi
host
rsv
influenza
virus
piv
like
caus
sever
ill
pneumonia
lead
hospit
immunocompromis
person
howev
virus
less
prone
produc
lower
respiratori
ill
highli
preval
rhinovirus
may
frequent
associ
sever
ill
although
gener
consid
respiratori
virus
herp
virus
known
produc
respiratori
infect
diseas
sometim
sever
immunocompromis
patient
tabl
histor
import
viru
measl
viru
rare
encount
widespread
vaccin
limit
avail
antivir
vaccin
acut
respiratori
virus
mean
infect
continu
import
mani
year
dictat
need
util
infect
control
procedur
much
possibl
particularli
hospit
institut
minim
spread
effort
develop
specif
vaccin
import
use
could
prevent
well
reduc
exposur
cancer
patient
virus
develop
specif
antivir
import
use
immunocompromis
patient
normal
recoveri
mechan
may
serious
impair
